AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02851199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Description: Electroencephalograph recording following hyperventilation in different participant's body postures
Study NCT03272646 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: gastric resection or total gastrectomy
Study NCT02081365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Dental Anxiety Treatment
Description: The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
Study NCT01559090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Study NCT01559090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Study NCT01559090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
Study NCT02733107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib, 250mg daily, po, continue until disease progression
Study NCT02733107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
Study NCT02653274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast porridge
Description: 220 kcal breakfast porridge served with 240 mL glass of water
Study NCT02207361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin
Description: Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
Study NCT02207361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Epirubicin
Description: Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
Study NCT02023203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Extraperitoneal laparoscopic inguinal hernia repair
Description: Laparoscopic hernioplasty
Study NCT02023203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally Extraperitoneal laparoscopic inguinal hernia repair
Description: Laparoscopic hernioplasty
Study NCT01781702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelubiprofen 30 mg
Study NCT01781702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex 200 mg
Study NCT02239185 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hernial sac ligation in continuity
Description: Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
Study NCT02239185 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hernial sac disconnection
Description: Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
Study NCT04519814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selective laser trabeculoplasty (SLT)
Description: Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
Study NCT04136028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
Study NCT03356067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric endoscopic peroral pyloromyotomy
Description: G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~1. Mucosal incision at the greater curvature 3-5 cm from the pylorus~2. Submucosal tunnelling~3. Finding pyloric sphincter~4. Myotomy (2-3 cm) of the pyloric muscle~5. Incision closure (endoclips or suture device)
Study NCT03356067 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Esophago-gastro-duodenoscopy
Description: Standard endoscopic examination of the upper GI tract with flexible endoscope
Study NCT00052559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00052559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00052559 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study NCT00052559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00052559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03564275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Boost
Description: 13-15 treatments with proton therapy given as a boost to standard of care photon therapy
Study NCT00219401 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal 7 valent conjugate vaccine (Prevenar®)
Description: Accelerated PCV vaccinaton.
Study NCT00219401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7 valent conjugate vaccine (Prevenar®)
Description: Accelerated PCV vaccinaton.
Study NCT03693222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
Study NCT03693222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
Study NCT02942147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
Study NCT02793908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleyris
Description: Luteal phase will be supplemented starting by the ovulation day for 14 days
Study NCT02793908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone8
Description: Luteal phase will be supplemented starting by the ovulation day for 14 days
Study NCT02099799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer and Website
Description: Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
Study NCT03431675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Single-dose oral ciprofloxacin
Study NCT03037957 — intervention group
Intervention type: DEVICE
Intervention: ARIES Group A Strep Assay
Study NCT02859545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Validation Training for Romantic Partners
Description: In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
Study NCT02859545 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Chronic Pain Education Training for Romantic Partners
Description: In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
Study NCT00840645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral
Study NCT01070784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler (Budesonide/formoterol)
Description: 2 x 160/4.5 microgram, inhalation, bid, 52 weeks
Study NCT01070784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: any available COPD treatment; investigator to decide
Description: According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
Study NCT01641315 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.
Study NCT01641315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.
Study NCT01704248 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye Drop Guide technique
Description: 1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward.
Study NCT01704248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine self-instillation technique
Description: 1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye.
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual blood pressure management
Study NCT04474145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comb group
Description: Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection.
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Description: Undergo blood pressure measurement
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Management
Description: Undergo intensive systolic BP management
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04467021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03520023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consult
Description: Consult of hospital palliative care service for those meeting study inclusion criteria
Study NCT00426751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
Study NCT00426751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
Study NCT01185535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: times of topical anesthesia for glottis
Description: topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
Study NCT02244359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study NCT02244359 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Study NCT02235753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training, short interval
Description: The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
Study NCT02942147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional or Pulse Radiofrequency
Description: In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
Study NCT02235753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training, long interval
Description: The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
Study NCT02232516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT02232516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT02232516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01468727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol wipe
Description: Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
Study NCT01468727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo wipe
Description: Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
Study NCT02313935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLM
Description: LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
Study NCT02313935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFA
Description: PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
Study NCT02313935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness
Description: CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
Study NCT02313935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VideoGrade
Description: Active cognitive training by use of the VideoGrade software by AUTH.
Study NCT01565629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer assisted cognitive behavioral therapy.
Description: Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
Study NCT03511261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Curcumin mucoadhesive gel
Description: Group 1 10%of mucoadhesive gel for topical application two times per day.
Study NCT03511261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin capsules 500mg
Description: Group 2 curcumin 500 mg capsules for oral intake two times per day
Study NCT03511261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% curcumin mucoadhesive gel + Curcumin capsules 250 mg
Description: Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day